Paignton

Researchers are evaluating the safety, antiviral response, and effectiveness of inhaled SNG001 in patients who require invasive mechanical ventilation due to respiratory virus infections like influenza, RSV, and coronaviruses. This Phase 2 study aims to determine if SNG001 can speed up virus clearance and reduce death rates compared to standard care. The study is sponsored by Synairgen Research Ltd. and involves two parts based on age and immune status. Participants will receive either SNG001 or a placebo inhaled once daily via the Solo nebuliser for up to 14 days while in the hospital. In Part 1, patients aged 50 and older will be given either SNG001 or placebo to assess safety. In Part 2, participants aged 18 to 50 with immunocompromising conditions, and those over 50 regardless of immune status, will receive SNG001 or placebo to evaluate its effectiveness. During the study, researchers will monitor adverse events, mortality within 28 days, and other health outcomes such as time to extubation, ventilator-free days, ICU and hospital stay duration, and virus clearance. Tests will include virus detection, biomarker levels, and organ support needs. Follow-up assessments will continue up to 42 days after randomization to ensure thorough safety and efficacy evaluations.